Metsera Inc. (NASDAQ:MTSR) Receives $55.75 Consensus Target Price from Analysts

Shares of Metsera Inc. (NASDAQ:MTSR) have been given an average rating of “Hold” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $55.75.

MTSR has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Metsera in a report on Wednesday, October 8th. Wells Fargo & Company cut shares of Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price objective for the company. in a research report on Tuesday, September 30th. Bank of America upped their target price on shares of Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Leerink Partners reissued a “market perform” rating and issued a $57.00 price target (down previously from $77.00) on shares of Metsera in a report on Wednesday, September 24th. Finally, Wall Street Zen raised Metsera from a “sell” rating to a “hold” rating in a report on Wednesday, October 1st.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its stake in shares of Metsera by 1.1% during the third quarter. Legal & General Group Plc now owns 23,491 shares of the company’s stock worth $1,229,000 after buying an additional 245 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Metsera by 45.5% during the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock valued at $27,000 after acquiring an additional 296 shares during the last quarter. Swiss National Bank lifted its stake in shares of Metsera by 1.5% in the 3rd quarter. Swiss National Bank now owns 40,700 shares of the company’s stock valued at $2,130,000 after purchasing an additional 600 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock valued at $46,000 after purchasing an additional 800 shares during the period. Finally, Penserra Capital Management LLC bought a new position in shares of Metsera in the 3rd quarter worth $50,000.

Metsera Stock Performance

Shares of NASDAQ:MTSR opened at $70.50 on Thursday. The company has a market capitalization of $7.42 billion and a PE ratio of -11.16. The company’s fifty day moving average is $53.47 and its 200-day moving average is $39.14. Metsera has a 52 week low of $12.30 and a 52 week high of $83.86.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.